AB0985 EVALUATION OF SERUM CALPROTECTIN (MRP-8/MRP-14) LEVEL IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS

Tetiana Marushko1, Yulia Holubovska1, Yuri Marushko2, Shupyk National Medical Academy of Postgraduate Education, Pediatrics N02, Kyiv, Ukraine; Bogomolets National Medical University, Pediatrics postgraduate education, Kyiv, Ukraine

Background: Evaluation of inflammatory activity is an important element in the management of patients with juvenile idiopathic arthritis (JIA), for which C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are traditionally used. However, they might be uninformative in case of subclinical inflammation. The serum level of calprotectin MRP-8/MRP-14 (sCal) correlates well with arthritis activity, as it is produced by activated cells directly in synovia.

Objectives: We evaluate the level of sCal in patients with JIA depending on the type of therapy in order to assess comprehensively the disease activity for further treatment correction.

Methods: 74 patients with JIA were examined, 18 of them had oligoarticular disease subtype, 39 – polyarticular, 17 – systemic. The mean age was 11.3 ± 0.4 years; the disease duration was 5.2 ± 0.4 years. Among them, there were 49 (66%) females and 25 (34%) males. All patients were divided into 2 groups depending on the therapy type. Group I consisted of 33 children treated with methotrexate, while 11 of them were in a state of clinical remission. Group II included 41 children treated with biologic DMARDs (adalimumab, etanercept, tocilizumab), while 13 of them achieved clinical remission. All children had normal levels of CRP and ESR. Quantitative indicators distribution is given as a median [5th; 95th percentile], the calculations were carried out using the Mann-Whitney U test.

Results: Level of sCal in the active disease stage in children of Group I was 8,750 ng/ml [3,700; 17,100], while sCal level in Group II was 2,900 ng/ml [1,200; 24,900]; sCal level in children of Group I which achieved clinical remission – 3,400 ng/ml [1,200; 6,000], and the same indicator in Group II – 1,000 ng/ml [100; 2,800]. sCal level was significantly higher in the group of patients who did not receive biologic DMARDs, both in the active stage of disease (p = 0.000006, U = 71.5) and in the stage of clinical remission (p = 0.000034, U = 11). sCal level is 5,800 ng/ml less in patients with active stage of disease and 2,400 ng/ml less in patients with clinical remission, both treated with biologic DMARDs. In addition, the level of sCal is 5.5 times higher in our patients (3,300 ng/ml) compared with healthy children (600 ng/ml) (p = 0.015). The moderate positive correlation of sCal and JADAS-27 activity index (r-Spearman’s = 0.58) was credibly established.

Conclusion: The level of sCal can reflect the degree of inflammatory activity in JIA, it is significantly higher in the group of patients who did not receive biologic DMARDs in the treatment regimen, both in the active disease stage (p = 0.000006, U = 71.5) and in the stage of clinical remission (p = 0.000034, U = 11), which indicates the effectiveness of biologic DMARDs in the treatment of JIA. We assume that it would be appropriate to estimate the serum calprotectin level in the comprehensive analysis of clinical status in JIA patients for the further correction of therapy.

Disclosure of Interests: None declared


AB0986 VITAMIN D LEVEL AND BONE MINERAL DENSITY IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS

Tetiana Marushko1, Yulia Holubovska1, Yuri Marushko2, Shupyk National Medical Academy of Postgraduate Education, Pediatrics N02, Kyiv, Ukraine; Bogomolets National Medical University, Pediatrics postgraduate education, Kyiv, Ukraine

Background: An impaired bone metabolism is observed in patients with juvenile idiopathic arthritis (JIA), associated both with the activation of pro-inflammatory cytokines and use of steroid medications. The majority of children with JIA have low vitamin D level, which may complicate the disease course. We regard the monitoring of bone mineral density (BMD) in patients with juvenile rheumatoid arthritis (JRA) should be complemented with an additional assessment of calcidiol (25(OH)D) serum level as an indicator of BMD and a criterion of successful therapy.

Objectives: To evaluate the bone densitometry data and calcidiol level in patients with JRA in order to estimate the osteogenic syndrome and the advisability of prescribing the vitamin D additional doses.

Methods: The calcidiol level and BMD data in 65 patients with JIA were assessed (41 girls and 24 boys). All children were divided into 2 groups depending on the therapy type. Group I consisted of patients who received methotrexate (n = 37), Group II – patients who received the biological DMARDs (n = 28), namely tocilizumab (6 patients), adalimumab (20 patients) and etanercept (2 patients). At the time of the study, 14 children of the Group II were prescribed the biological DMARDs only, while the 12 patients were in the state of clinical remission unlike the 7 patients of Group I. It should be mentioned that the majority of children in the Group II had high disease activity degrees before the start of treatment with biological DMARDs. In order to show the correlation between BMD and disease activity, cJADAS-27 score result for the last 6 months was estimated. The data were processed using Pearson’s chi-squared test and Spearman’s Rank correlation coefficient.

Results: The study revealed, 60 children (92% of all patients) showed vitamin D insufficiency, that mainly manifested by decreased calcidiol level (from 21 to 29 ng/ml), only 8 children (12%) showed calcidiol level deficiency (<20 ng/ml). A significant difference was found in the BMD results depending on the therapy type (χ2 = 10.05; p <0.01) using Pearson’s chi-squared test. As a result, children who received biological DMARDs, demonstrated significantly better results according to BMD assessment data. A direct association of moderate strength was found (the correlation coefficient (r-Spearman’s) is 0.39). The strong negative association (r-Spearman’s was -0.72) was observed between BMD assessment data and cJADAS-27 score result, which confirmed our statement – high disease activity affects the bone tissue mineralization. There was a weak negative association between 25(OH)D level and cJADAS-27 score result (r-Spearman’s was -0.15).

Conclusion: There was a paucity of vitamin D level in 92% of patients with JRA, in 80% secondary osteopenic syndrome. It was revealed that patients, who receive biological DMARDs in integrated treatment, demonstrate significantly better results according to BMD assessment data. Calcidiol level has a moderate effect on BMD, while BMD strongly depends on disease activity degree according to the Spearman’s Rank correlation coefficient.

Disclosure of Interests: None declared


AB0987 CHOICE AND SWITCH BETWEEN BIOLOGICAL AGENTS IN NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (JIA)

Anna Ignatova1, Elena Zholobova2, Shupyk National Medical Academy of Postgraduate Education, Pediatrics N02, Kyiv, Ukraine; Bogomolets National Medical University, Pediatrics postgraduate education, Kyiv, Ukraine

Background: Over the past few decades, biologic therapy has significantly improved the prognosis in children with JIA. The issue of optimal and personalised biologics prescription and the problem of switching between drugs are relevant questions of modern paediatric rheumatology.

Disclosure of Interests: None declared